ReviewClinical and experimental immunology2005
The immune recognition of gluten in coeliac disease.
Review in Clinical and experimental immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.
- A large meta-analysis identifies genes associated with anterior uveitis.Nature communications · 2023Pooled it
- Parental perspectives on gluten immunogenic peptide urine testing in children with coeliac disease: a qualitative study on barriers, emotions and interest in point-of-care tools.BMJ open gastroenterology · 2026Article
- Genotype and Agronomic Management Interactions Shape the Accumulation of Immunogenic and Toxic Gluten Peptides in Durum Wheat.Journal of agricultural and food chemistry · 2026Article
- From gluten to therapeutics: molecular mechanisms of celiac disease and emerging alternatives to the gluten-free diet.Frontiers in pharmacology · 2026Review
- Gluten Proteins: Beneficial Factors and Toxic Triggers in Human Health.Foods (Basel, Switzerland) · 2025Review
- Unraveling the role of early coeliac disease diagnosis in the risk of developing immune-mediated renal diseases.BMC gastroenterology · 2025Article
- Beyond the Grain: Navigating the Intersection of Gluten-Free Diets, Celiac Disease, and Cardiovascular Health.Cureus · 2024Review
- The role of tryptophan metabolism and tolerogenic dendritic cells in maintaining immune tolerance: Insights into celiac disease pathogenesis.Immunity, inflammation and disease · 2024Review
- Functional Bioactivities of Soluble Seed Proteins from Two Leguminous Seeds.Preventive nutrition and food science · 2023Article
- Gluten Exorphins Promote Cell Proliferation through the Activation of Mitogenic and Pro-Survival Pathways.International journal of molecular sciences · 2023Article
- New Developments in Celiac Disease Treatment.International journal of molecular sciences · 2023Review
- Prediction of celiac disease associated epitopes and motifs in a protein.Frontiers in immunology · 2023Article
- Impact of Nutritional Profile on Gut Microbiota Diversity in Patients with Celiac Disease.Current microbiology · 2022Article
- Comparative Study on the Exacerbating Effects of Casein-Rich vs. Gluten-Rich Diets on Biochemical-Induced Features in Rodent Model of Autism.Journal of molecular neuroscience : MN · 2022Article
- Characterization of the "gut microbiota-immunity axis" and microbial lipid metabolites in atrophic and potential celiac disease.Frontiers in microbiology · 2022Article
- E40 glutenase detoxification capabilities of residual gluten immunogenic peptides inFrontiers in nutrition · 2022Article
- Review
- Contribution of Infectious Agents to the Development of Celiac Disease.Microorganisms · 2021Review
- Gliadin Sequestration as a Novel Therapy for Celiac Disease: A Prospective Application for Polyphenols.International journal of molecular sciences · 2021Review
- Significance of PD1 Alternative Splicing in Celiac Disease as a Novel Source for Diagnostic and Therapeutic Target.Frontiers in immunology · 2021Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coeliac disease, the most common intestinal disorder of western populations, is an autoimmune enteropathy caused by an abnormal immune response to dietary gluten peptides that occurs in genetically susceptible individuals carrying the HLA-DQ2 or -DQ8 haplotype. Despite the recent progresses in understanding the molecular mechanisms of mucosal lesions, it remains unknown how increased amounts of gluten peptides can enter the intestinal mucosa to initiate the inflammatory cascade. Current knowledge indicates that different gluten peptides are involved in the disease process in a different manner, some fragments being 'toxic' and others 'immunogenic'. Those defined as 'toxic' are able to induce mucosal damage either when added in culture to duodenal endoscopic biopsy or when administered in vivo, while those defined as 'immunogenic' are able to specifically stimulate HLA-DQ2- or DQ8-restricted T cell clones isolated from jejunal mucosa or peripheral blood of coeliac patients. These peptides are able to trigger two immunological pathways: one is thought to be a rapid effect on the epithelium that involves the innate immune response and the other represents the adaptive immune response involving CD4+ T cells in the lamina propria that recognize gluten epitopes processed and presented by antigen presenting cells. These findings are the subject of the present review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.